Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867541 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL23039308 | 0.83 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL6534956 | 0.81 | VCAM1 (0.46) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL8063524 | 0.81 | VCAM1 (0.46) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL17558407 | 0.81 | EPHX2 (0.37) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL6515361 | 0.79 | TP53 (0.37) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL306135 | 0.79 | TSHR (0.51) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL8668862 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL30729473 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL7077212 | 0.78 | ALDH1A1 (0.36) | ALDH1A1CYP1A2CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812226-B2 | FOR THERAPY OF RHEUMATOID ARTHRITIS, EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| EP-1242396-B1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | ALDH1A1 2046/4885CYP1A2 903/4885CYP2D6 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.